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The LRRK2 G2019S mutation is found at higher frequency among Parkinson
disease (PD) patients of Ashkenazi Jewish (AJ) ancestry. This study was
designed to test whether an internet-based approach could be an effective
approach to screen and identify mutation carriers. Individuals with and without
PD of AJ ancestry were recruited and consented through an internet-based
study website. An algorithm was applied to a series of screening questions to
identify individuals at increased risk to carry the LRRK2 G2019S mutation.
About 1000 individuals completed the initial screening. Around 741 qualified
for mutation testing and 650 were tested. Seventy-two individuals carried at
least one LRRK2 G2019S mutation; 38 with PD (12.5%) and 34 without
(10.1%). Among the AJ PD participants, each affected first-degree relative
increased the likelihood the individual was LRRK2+ [OR = 4.7; 95% confidence
interval = (2.4–9.0)]. The same was not observed among the unaffected AJ sub-
jects (P = 0.11). An internet-based approach successfully screened large num-
bers of individuals to identify those with risk factors increasing the likelihood
that they carried a LRRK2 G2019S mutation. A similar approach could be
implemented in other disorders to identify individuals for clinical trials,
biomarker analyses and other types of research studies.
Introduction
Parkinson disease (PD) is the second most frequent neuro-
degenerative disorder among the elderly. Familial forms of
PD comprise only 10% of cases (Elbaz et al. 1999) but have
yielded important pathophysiological insights through the
identification of novel genes contributing to PD suscepti-
bility. Mutations in five genes result in Mendelian forms of
PD. Two genes, leucine-rich repeat kinase 2 (LRRK2) and
synuclein, alpha (non-A4 component of amyloid precur-
sor) (SNCA), are mutated in autosomal dominant forms of
PD. Three genes, parkin RBR E3 ubiquitin protein ligase
(PARK2), DJ1 (PARK7) and PTEN-induced putative kinase
1 (PINK1) are mutated in autosomal recessive forms of PD.
The LRRK2 G2019S mutation is the most common,
single cause of PD that has been identified to date. This
mutation is found at higher frequency in populations
from Northern Africa as well as individuals of Ashkenazi
(Eastern European) ancestry. Among PD patients of Ash-
kenazi Jewish (AJ) ancestry, screening studies have found
the frequency of the LRRK2 G2019S mutation to be as
high as 15–20% (Orr-Urtreger et al. 2007; Ozelius et al.
2006). The penetrance of this mutation has been reported
to be reduced (Goldwurm et al. 2007; Healy et al. 2008;
Hentati et al. 2014; Hulihan et al. 2008; Latourelle et al.
2008; Troiano et al. 2010), with the most recent estimates
suggesting that the penetrance may be as low as 30% at
age 80 years (Marder et al. 2014).
The Parkinson’s Progression Markers Initiative (PPMI)
is an observational clinical study using advanced imaging,
biologic sampling, and clinical and behavioral assessments
to identify biomarkers of PD progression. The focus of
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PPMI is to identify individuals at greatest risk of develop-
ing PD in order to detect biomarkers of phenoconversion
and early disease progression. One of the challenges to
identify these biomarkers is the identification of individu-
als at increased risk of PD in whom biomarkers could be
monitored. One approach to identify individuals at
increased risk of PD is to enrich for subjects more likely
to have genetic risk factors, such as the LRRK2 G2019S
mutation. Even with the availability of this risk factor, it
is still financially costly and time consuming to screen
large numbers of individuals to identify those that carry
this mutation.
The PPMI study has developed an innovative approach
to screen large numbers of individuals from enriched
populations. In this study, we focused on the recruitment
of individuals of AJ ancestry and then further enriched
the sample by asking about a family history of PD. To
reduce costs, all individuals completed their screening
and consenting process online and provided a saliva sam-
ple through the mail for genetic testing. As we describe in
this report, our strategy has proven extremely successful
and led to the identification of a large number of individ-
uals, both with and without a diagnosis of PD, who carry
a LRRK2 G2019S mutation. These individuals have now
been invited to participate in the biomarker aspect of the
PPMI study.
Methods
Outreach and participant screening
The Michael J. Fox Foundation prepared recruitment
material that highlighted the higher frequency of the
LRRK2 G2019S mutation in the AJ population. The
recruitment materials were widely distributed through
print, e-mail and in-person campaigns to individuals of
AJ ancestry. In addition, recruitment materials were also
distributed broadly by the Michael J. Fox Foundation to
individuals interested in PD research. Interested individu-
als were directed to the Michael J. Fox Foundation PPMI
website for an initial screening to determine if they had
risk factors that indicated an increased risk of a LRRK2
mutation (Fig. 1). Individuals who met the initial criteria
were then provided a link which directed them to a web-
site at Indiana University.
The website at Indiana University presented a fact sheet
about LRRK2 and PD. Individuals could then choose to
continue to the online Informed Consent document. The
Informed Consent document described the study, pro-
vided additional information about LRRK2 and PD, and
provided the risks and benefits of study participation.
Individuals were then asked if they had any questions
about the study. If they indicated that they had questions,
they were asked to provide their name and contact infor-
mation so that study personnel could contact them to
answer their questions. Individuals who indicated that
they had questions were not given the option to agree to
the electronic consent or continue with the screening
process until after they had been contacted by study per-
sonnel. If the individual did not have any questions, they
indicated that they agreed to the terms of the Informed
Consent form by providing their name. They were then
asked to provide their contact information (mailing
address, e-mail address and telephone number).
After providing their contact information, the partici-
pant was directed to an online study case report form
(Fig. 1). Participants were asked a series of questions to
determine whether they had risk factors that would
increase the likelihood that they carried a LRRK2 G2019S
or R1441G mutation (Table 1). Questions included
whether or not they had PD, if they were of AJ ancestry,
and whether or not they had a first-degree relative with
PD. An algorithm based on the participant’s responses
determined the individual’s eligibility to participate in the
next phase of the study (Fig. 2). Individuals with a diagno-
sis of PD had to report AJ ancestry and/or a first-degree
relative with PD to qualify to receive genetic testing. To
qualify for genetic testing, participants who did not have a
diagnosis of PD were required to be of AJ ancestry and to
also have a first-degree relative with PD. Any individual,
regardless of PD status, who reported a first-degree relative
with a LRRK2 mutation also qualified for genetic testing. A
map of the US PPMI sites was displayed and participants
were reminded that participation in the full PPMI study
would require that they visit a PPMI site several times over
the upcoming years. They were then asked to select the
PPMI site that would be most convenient for them to go
to for study visits. At the end of the screening questions
and site selection, the individual received a message indi-
cating whether they were eligible to participate in the
genetic screening phase of the study.
Individuals who responded that they had already
undergone genetic testing were informed that they would
be contacted and asked to send a copy of their test results
to the study coordinator for verification. If a positive test
result was verified, the individual was offered genetic
counseling and then referred directly to a PPMI site to
learn more about the PPMI study.
Sample collection and genetic testing
After completing the online screening, each participant
was contacted to review their responses and confirm that
they wished to receive a saliva collection kit from which
DNA would be obtained. Once confirmed, an Oragene
DISCOVER (OGR-500) kit (DNA Genotek Inc., Kanata,
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Ontario, Canada) was shipped to them by mail along with
directions for saliva collection. The sample was then
shipped back to Indiana University. Samples received at
Indiana University were sent for genetic testing at Massa-
chusetts General Hospital. Samples were tested for the
LRRK2 G2019S or LRRK2 R144G mutation based on the
participant’s response to the screening questions.
Genomic DNA was extracted from patients’ peripheral
leukocytes (blood) or buccal epithelial cells (saliva) using
QIAcube DNA Purification System by QIAGEN (Valen-
cia, CA). The standard protocols provided by the manu-
facturer were followed. Patient DNA was PCR amplified
using appropriate primer pairs depending on the specific
mutation screened (LRRK2 exon 31 c.44321C>A,
p.Arg1441Gly; LRRK2 exon 41 c.6055G>A, p.Gly2019Ser).
The primers were manufactured by Invitrogen (Life Tech-
nologies, Grand Island, NY) and each primer pair was
used to amplify its corresponding exon and the adjacent
intronic sequences. Positive mutations were identified by
comparison of bidirectional sequence data against refer-
ence sequence.
Genetic testing results were sent by Massachusetts Gen-
eral Hospital to Indiana University. An appointment was
made for the genetic counselor to review the genetic test-
ing results with the participant by telephone. Following
counseling, the participant was provided with a written
summary of the genetic testing results and counseling
session.
Statistical analysis
Logistic regression was performed to identify those vari-
ables that predicted whether an individual was LRRK2
positive (LRRK2+) or LRRK2 negative (LRRK2). Due to
the differential screening criteria for affected and unaf-
fected individuals, analyses were performed in each group
separately. Analyses performed in the two subject groups
of AJ descent (PD and unaffected) included as potential
predictors age, gender and the number of first-degree rel-
atives with PD. Secondary analyses were performed test-
ing for the effect of each type of relative with PD (father,
mother, brother, sister, offspring).
Results
The Michael J. Fox Foundation and Indiana University
websites were activated on February 25, 2014. All results
are reported for individuals who completed their consent
at the Indiana University site by September 1, 2014. Miss-
ing data or kits are truncated as of October 20, 2014. A
total of 2303 individuals completed the initial survey at
the Michael J. Fox Foundation website and 1193 individ-
uals qualified to be directed to the Indiana University
website for further screening (see Fig. 1).
A total of 967 individuals completed the consent pro-
cess at the Indiana University website. Responses to the
screening questions are shown in Table 1. Eighty-one
individuals reported having previous genetic testing which
they believed indicated they carried a LRRK2 mutation.
Sixty-four of these individuals were able to provide a
copy of their testing report to Indiana University for
review. Upon review of the genetic testing results, slightly
more than half of this group (53.1%) did not carry a
LRRK2 G2019S mutation. The majority of these results
were from testing performed by 23andMe. Of the remain-
ing 17 individuals who indicated previous testing, 4 could
Figure 1. Study overview.
3ª 2015 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
T. Foroud et al. Recruitment of LRRK2 Mutation Carriers
not be reached by the study coordinator and 13 could
not produce a copy of their results. For those 13 unable
to provide their test results, responses to the screening
questions were used to determine eligibility for a genetic
testing.
Table 2 summarizes basic demographic information for
the 899 individuals who completed the screening ques-
tions at the Indiana University website to determine eligi-
bility for genetic testing. Of these 899 individuals, 395
reported a diagnosis of PD and 504 did not. The study
coordinator attempted to contact all individuals to verify
their screening responses. Of note, 14 individuals who
had reported AJ ancestry during the survey reported that
they were not actually of AJ descent during these calls,
and eight individuals who had reported a relative with a
known LRRK2 mutation could not confirm that such test-
ing had been performed.
An algorithm was applied to determine eligibility for
genetic testing (Fig. 2). Individuals with a diagnosis of
PD had to report at least one of the following to qualify:
(1) AJ ancestry (n = 299); (2) first-degree relative with
PD (n = 58); or (3) first-degree relative with a LRRK2
mutation (n = 1). A total of 358 individuals with PD met
these requirements for a saliva kit. Individuals who did
not have a diagnosis of PD were required to meet one of
the two following criteria: (1) have a first-degree relative
with a LRRK2 mutation (n = 18); or (2) be of AJ ancestry
and have a first-degree relative with PD (n = 391). About
409 unaffected individuals met these requirements for a
saliva kit used for genetic testing.
Only a small number (n = 26) who qualified to receive
a saliva kit elected not to do so or could not be reached
by the study coordinator to confirm participation. Among
the 741 individuals sent a saliva kit, 650 (87.7%) returned
the filled kit to Indiana University. The vast majority of
individuals were screened for the LRRK2 G2019S muta-
tion (99.9%). Only five individuals qualified to be
screened for the LRRK2 R1441G mutation in addition to
the LRRK2 G2019S, and one for the LRRK2 R1441G
mutation only. None of the subjects were positive for the
LRRK2 R1441G mutation.
LRRK2 G2019S testing results were available for a total
of 642 individuals (Table 1). Results for 5 individuals were
still pending and 3 samples failed when tested. This group
of 642 individuals included 305 with a diagnosis of PD
(47.5%) and 337 who did not. The total number of indivi-
duals carrying a LRRK2 G2019S mutation was 72 (11.2%).
Among those with PD, the number carrying a LRRK2
G2019S mutation was 38 (12.5%) and among those with-
out a diagnosis of PD, the number was 34 (10.1%). There
were two individuals who were homozygous for the LRRK2
G2019S mutation. Both had been previously diagnosed
with PD; however, only one had a family history of PD.
The family history question on the screening survey
was a strong predictor of LRRK2 mutation status. A
majority (76.4%) of individuals found to have a LRRK2
G2019S mutation had at least one relative with PD, and
9.7% reported more than one relative with PD. Among
those carrying the LRRK2 mutation, the most frequently
reported relative with PD was a parent; 36.1% reported









1. Do you have Parkinson disease? Yes 305 (47.5) 38 (52.8) 267 (46.8)
No 337 (52.5) 34 (47.2) 303 (53.2)
2. Have you previously been tested for a possible
LRRK2 gene mutation? (no report found to be available)
Yes 13 (2.0) 5 (6.9) 8 (1.4)
No 582 (90.7) 60 (83.3) 522 (91.6)
Do not know 47 (7.3) 7 (9.7) 40 (7.0)
3. Are you of Eastern European (Ashkenazi) Jewish descent? Yes 579 (90.2) 67 (93.1) 512 (89.8)
No 43 (6.7) 3 (4.2) 40 (7.0)
Do not know 20 (3.1) 2 (2.3) 18 (3.2)
4. Are you of Basque (Northern Spain) descent?
(newer question, 356 responding)
Yes 3 (0.8) 0 (0.0) 3 (0.5)
No 335 (94.1) 35 (48.6) 300 (52.6)
Do not know 18 (5.1) 4 (5.6) 14 (2.5)
5. Do any of the following also have PD? Father 222 (34.6) 26 (36.1) 196 (34.4)
Mother 161 (25.1) 25 (34.7) 136 (23.9)
Brother 50 (7.8) 5 (6.9) 45 (7.9)
Sister 35 (5.5) 5 (6.9) 30 (5.3)
Children 9 (1.4) 1 (1.4) 8 (1.4)
6. Do you have a first-degree relative
(father, mother, full sibling, child) with a
positive LRRK2 gene test?
Yes 57 (8.9) 12 (16.7) 44 (7.7)
No 143 (22.3) 14 (19.4) 129 (22.6)
Do not know 443 (69.0) 46 (63.9) 397 (69.6)
4 ª 2015 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
Recruitment of LRRK2 Mutation Carriers T. Foroud et al.
their father with PD, and 34.7% reported an affected
mother. Two LRRK2 G2019S heterozygotes (2.8%)
reported both their parents had PD.
Of the individuals with LRRK2 G2019S testing results
available, there were 254 AJ individuals with PD.
Although the majority did not carry a LRRK2 mutation
(n = 219, 86.2%), there were 35 individuals who did
(13.8%). Neither age nor gender were significant predic-
tors of LRRK2 mutation status (P > 0.94). However, the
number of affected relatives was a significant predictor of
mutation status (Wald v2 = 21.0, df = 1,
P < 4.9 9 106). For each additional affected first-degree
relative, the odds that the study participant had a LRRK2
mutation increased by 4.7 [95% confidence interval
(CI) = (2.4–9.0)]. Secondary analyses revealed that having
an affected father significantly increased the odds the par-
ticipant carried a LRRK2 mutation by 3.7 [P = 0.01, 95%
CI = (1.4–9.8)]. If the participant’s mother was affected,
the odds the participant was LRRK2+ more than doubled,
with an odds ratio of 8.1 [P = 3.9 9 105, 95%
CI = (3.0–22.1)].
Of the individuals with results available, there were 325
AJ individuals who did not report a diagnosis of PD. Of
those, 293 were LRRK2 (90.1%), and 32 were LRRK2+
(9.9%). None of the tested variables was a significant pre-
dictor of LRRK2 status (gender P = 0.83, age at interview
P = 0.08, number of relatives P = 0.11).
Discussion
The identification of individuals who have inherited a
LRRK2 mutation is challenging. In this study, we designed
an efficient approach that allowed us to screen nearly
1000 individuals to determine if they carried risk factors
that increased the likelihood that they carried a LRRK2
mutation. With this strategy, we newly identified 72
individuals who carry a LRRK2 G2019S mutation and also
confirmed the result for 30 individuals who had received
previous genetic testing. Thus, in only 6 months, we iden-
tified over 100 individuals who qualified to participate in
the PPMI biomarker study focused on longitudinal evalu-
ation of individuals carrying a LRRK2 G2019S mutation.
Figure 2. Screening algorithm.
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Previous studies have reported that approximately 15–
20% of PD patients of AJ ancestry carry the LRRK2
G2019S mutation. In this study, we found a rate of
12.5%. This is slightly lower than the previously reported
rate, but still supports the higher frequency of this muta-
tion in this population. Prior to initiating this study, we
predicted that unaffected individuals of AJ ancestry who
had a first-degree relative with PD would also have an
elevated frequency of the G2019S mutation. We antici-
pated that this rate would be half that of the PD popula-
tion. In this study, we found the rate to be 10.2%,
slightly higher than we would have anticipated. This may
be in part due to some unaffected individuals being
referred to the study by a family member who learned of
their LRRK2 carrier status.
From this study, we confirmed the importance of col-
lecting family history information prior to genetic testing
for the LRRK2 G2019S mutation. Individuals with PD were
not required to have another family member with PD to
qualify for genetic testing. However, the presence of each
additional affected family member with a mutation
increased the likelihood that an AJ individual with PD car-
ried the LRRK2 mutation by 4.7%. Individuals who were
unaffected were not eligible for genetic testing unless they
had a first-degree relative with PD. We found that among
this group, the number of additional affected family mem-
bers was not a significant predictor of LRRK2 status.
We did find that individuals with an affected parent
were more likely to carry a LRRK2 mutation as compared
with those who did not have an affected parent. Further-
more, in our study, having an affected mother was a
stronger predictor of LRRK2+ status as compared with an
affected father. These results appear to be consistent with
an earlier study by Alcalay et al. (2013) which found that
the penetrance of LRRK2 G2019S may be higher in
women than men. If female carriers of the LRRK2 muta-
tion are more likely to be affected, we would expect to
find more affected mothers than affected fathers in our
sample. This finding requires further evaluation in addi-
tional samples.
Potential study participants appeared to be unsure of
previous genetic testing in family members. On the initial
screen, 92 individuals reported that a family member had
been previously tested and found to carry a LRRK2 muta-
tion. When the subject was contacted by the study coor-
dinator to confirm this information, the majority was
unable to confirm that a genetic test had been performed
and was positive. In these cases, if the subject still met
criteria for genetic testing, they were sent a saliva kit. If
they did not qualify for a genetic testing, they did not
participate further in the study.
The cost of recruiting subjects through an internet-
based strategy as used in this study is difficult to quantify.
Study personnel developed the website and databases
required for this study. A full time coordinator was avail-
able to answer questions and also spoke by telephone to
each individual who qualified for genetic testing prior to
the shipping of the saliva kit. This personal interaction
likely increased the commitment of the study participants.
Surprisingly, few reminders to return a saliva kit were
required in this subject group. Anecdotally, subjects found
it convenient to participate in the study without leaving
their home. Thus, by coupling a convenient online partic-
ipation with a telephone call with study staff, we likely
ensured that those subjects who received the saliva kit
were likely to also return the kit and receive study results.
The approach used in this study could be applied quite
easily for the testing of other PD susceptibility genes or
to other disorders. We have just initiated recruitment for
another risk factor, glucocerebrosidase (GBA), using the
same study design. There is an ongoing study that has
implemented an internet-based program for AJ carrier
screening for multiple genetic disorders (Grinzaid et al.
2014). There is growing interest to utilize precision ge-
nomics, which will target disease treatment based on the
patient’s underlying genetic risk profile. It will be essential
that trials can be initiated that recruit participants with
particular risk factors or mutations. Approaches such as
ours could dramatically increase the rate at which such
focused patient populations could be efficiently identified.
Table 2. Summary and demographic information for individuals who
completed initial screening at the Indiana University website by Janu-
ary 9, 2014.
Number % % M % PD
Consented through WRI site,
no previous testing
899 100 42 44
Qualified for genetic testing 767 85 45 47
Qualified and confirmed through WRI 741 82 45 47
Did not qualify through WRI 132 15 26 29
Unable to contact to confirm
further participation
15 2 20 47
Declined further participation in study 11 1 46 27
Kits sent 7411 100 45 47
Kits not returned 91 12 33 45
Kits with LRRK2 G2019S
results from MGH
642 87 47 48
LRRK2 G2019S 642 100 47 48
LRRK2 G2019S- 570 89 47 47
LRRK2 G2019S+ 72 11 44 53
Consented through WRI site, with
previous testing report available
64 100 41 66
LRRK2 G2019S- 34 53 35 79
LRRK2 G2019S+ 30 47 47 50
1Genetic testing results have not been received for 5 individuals, and
there were 3 sample failures.
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One weakness of the study was a targeted recruitment,
focused largely on individuals of AJ ancestry. Therefore,
the conclusions drawn about the participation rates and
the frequency of LRRK2 G2019S mutation are not appli-
cable to individuals of other ancestry. However, results
suggest that this recruitment strategy is successful in iden-
tifying an at-risk population. This study had several other
strengths. The population being recruited was highly
engaged, and for the most part had access to the internet.
Only a small number of individuals (<20) required the
screening questionnaire to be mailed to them because
they did not have internet access. As a group, this subject
population was motivated to participate fully in the study.
Among those who qualified for genetic testing based on
their screening questions, only 11 (1.4%) did not wish to
receive a saliva kit and 15 (2.0%) did not respond to the
coordinator’s telephone call to confirm their continued
participation. Upon receiving a saliva kit, 87.7% returned
the filled saliva kit. A total of 91 individuals (12.3%) did
not return their saliva kit. Given that this is a study con-
ducted largely by mail and the internet, the return rate
for the saliva kits is very high.
In summary, we used an internet-based approach to
screen large numbers of individuals to identify those with
risk factors increasing the likelihood that they carried a
mutation contributing to PD susceptibility. This was a
highly efficient approach that in only 6 months yielded
over 100 individuals who carried a LRRK2 mutation. We
believe that a similar approach could be implemented in
other disorders to identify individuals for clinical trials,
biomarker analyses, and other types of research studies.
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